Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
Background: The safety of bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and digestive and nondigestive cancers is poorly documented. Methods: We retrospectively evaluated patient records of all adult cancer patients with IBD at our institution from Ap...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/12/2914 |
| _version_ | 1797489231480750080 |
|---|---|
| author | Ruth Gabriela Herrera-Gómez Miruna Grecea Claire Gallois Valérie Boige Patricia Pautier Barbara Pistilli David Planchard David Malka Michel Ducreux Olivier Mir |
| author_facet | Ruth Gabriela Herrera-Gómez Miruna Grecea Claire Gallois Valérie Boige Patricia Pautier Barbara Pistilli David Planchard David Malka Michel Ducreux Olivier Mir |
| author_sort | Ruth Gabriela Herrera-Gómez |
| collection | DOAJ |
| description | Background: The safety of bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and digestive and nondigestive cancers is poorly documented. Methods: We retrospectively evaluated patient records of all adult cancer patients with IBD at our institution from April 2007 to May 2016 with an update in November 2019. Results: Twenty-seven patients with a history of IBD (Crohn’s disease, <i>n</i> = 22; ulcerative colitis, <i>n</i> = 5) who were treated with bevacizumab and chemotherapy for metastatic solid tumors were identified. At the time of advanced cancer diagnosis, 18 patients had quiescent IBD, whereas 9 patients had moderately active IBD. Among those with moderately active IBD, five had received corticosteroids less than six months prior to cancer diagnosis and one had received infliximab. The treated cancers were colorectal cancer (<i>n</i> = 13), small bowel cancer (<i>n</i> = 4), non-small cell lung cancer (<i>n</i> = 3), breast cancer (<i>n</i> = 3), and other cancers (<i>n</i> = 4). Patients received bevacizumab in combination with chemotherapy and/or as maintenance for a median of 6.7 months. Grade 2 or higher bevacizumab-related complications were proteinuria in two patients and hypertension, diarrhea, rectal bleeding, and intestinal perforation in one patient each. No clinical IBD flares were observed during bevacizumab treatment. Conclusion: Bevacizumab combined with chemotherapy is safe in cancer patients with moderately active or quiescent IBD. |
| first_indexed | 2024-03-10T00:13:33Z |
| format | Article |
| id | doaj.art-e75464e13e6b4f9e969e83585288d70b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:13:33Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e75464e13e6b4f9e969e83585288d70b2023-11-23T15:56:19ZengMDPI AGCancers2072-66942022-06-011412291410.3390/cancers14122914Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel DiseaseRuth Gabriela Herrera-Gómez0Miruna Grecea1Claire Gallois2Valérie Boige3Patricia Pautier4Barbara Pistilli5David Planchard6David Malka7Michel Ducreux8Olivier Mir9Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, 75015 Paris, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceDepartment of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, FranceBackground: The safety of bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and digestive and nondigestive cancers is poorly documented. Methods: We retrospectively evaluated patient records of all adult cancer patients with IBD at our institution from April 2007 to May 2016 with an update in November 2019. Results: Twenty-seven patients with a history of IBD (Crohn’s disease, <i>n</i> = 22; ulcerative colitis, <i>n</i> = 5) who were treated with bevacizumab and chemotherapy for metastatic solid tumors were identified. At the time of advanced cancer diagnosis, 18 patients had quiescent IBD, whereas 9 patients had moderately active IBD. Among those with moderately active IBD, five had received corticosteroids less than six months prior to cancer diagnosis and one had received infliximab. The treated cancers were colorectal cancer (<i>n</i> = 13), small bowel cancer (<i>n</i> = 4), non-small cell lung cancer (<i>n</i> = 3), breast cancer (<i>n</i> = 3), and other cancers (<i>n</i> = 4). Patients received bevacizumab in combination with chemotherapy and/or as maintenance for a median of 6.7 months. Grade 2 or higher bevacizumab-related complications were proteinuria in two patients and hypertension, diarrhea, rectal bleeding, and intestinal perforation in one patient each. No clinical IBD flares were observed during bevacizumab treatment. Conclusion: Bevacizumab combined with chemotherapy is safe in cancer patients with moderately active or quiescent IBD.https://www.mdpi.com/2072-6694/14/12/2914inflammatory bowel diseaseulcerative colitisCrohn’s diseasebevacizumabchemotherapycancer |
| spellingShingle | Ruth Gabriela Herrera-Gómez Miruna Grecea Claire Gallois Valérie Boige Patricia Pautier Barbara Pistilli David Planchard David Malka Michel Ducreux Olivier Mir Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease Cancers inflammatory bowel disease ulcerative colitis Crohn’s disease bevacizumab chemotherapy cancer |
| title | Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease |
| title_full | Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease |
| title_fullStr | Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease |
| title_full_unstemmed | Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease |
| title_short | Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease |
| title_sort | safety and efficacy of bevacizumab in cancer patients with inflammatory bowel disease |
| topic | inflammatory bowel disease ulcerative colitis Crohn’s disease bevacizumab chemotherapy cancer |
| url | https://www.mdpi.com/2072-6694/14/12/2914 |
| work_keys_str_mv | AT ruthgabrielaherreragomez safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT mirunagrecea safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT clairegallois safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT valerieboige safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT patriciapautier safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT barbarapistilli safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT davidplanchard safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT davidmalka safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT michelducreux safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease AT oliviermir safetyandefficacyofbevacizumabincancerpatientswithinflammatoryboweldisease |